Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
C

Curiox BioSystems Co Ltd
KOSDAQ:445680

Watchlist Manager
Curiox BioSystems Co Ltd
KOSDAQ:445680
Watchlist
Price: 114 400 KRW -0.78%
Market Cap: ₩2T
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

Assets
+
3Y
-
5Y
-
10Y
-
Liabilities
+
3Y
-
5Y
-
10Y
-
Equity
+
3Y
-
5Y
-
10Y
-

Balance Sheet Decomposition
Curiox BioSystems Co Ltd

Balance Sheet
Curiox BioSystems Co Ltd

Rotate your device to view
Balance Sheet
Currency: KRW
Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
11 003
5 597
17 909
Cash Equivalents
11 003
5 597
17 909
Short-Term Investments
8 816
3 125
0
Total Receivables
1 330
1 921
1 850
Accounts Receivables
1 247
1 864
1 793
Other Receivables
83
57
57
Inventory
1 759
2 911
1 621
Other Current Assets
152
397
221
Total Current Assets
23 060
13 949
21 601
PP&E Net
543
998
2 391
PP&E Gross
543
998
2 391
Accumulated Depreciation
656
923
2 072
Intangible Assets
10 969
10 761
10 056
Goodwill
21 143
22 733
23 547
Other Long-Term Assets
78
186
203
Other Assets
21 143
22 733
23 547
Total Assets
55 793
N/A
48 627
-13%
57 798
+19%
Liabilities
Accounts Payable
937
929
330
Accrued Liabilities
441
537
376
Short-Term Debt
0
0
0
Current Portion of Long-Term Debt
16 171
219
359
Other Current Liabilities
30 846
1 149
1 652
Total Current Liabilities
48 395
2 835
2 717
Long-Term Debt
242
168
606
Deferred Income Tax
1 564
1 764
1 592
Minority Interest
11
8
5
Total Liabilities
50 211
N/A
4 775
-90%
4 919
+3%
Equity
Common Stock
543
3 284
4 011
Retained Earnings
23 931
35 426
45 466
Additional Paid In Capital
27 944
71 651
88 955
Other Equity
1 027
4 344
5 379
Total Equity
5 582
N/A
43 853
+686%
52 879
+21%
Total Liabilities & Equity
55 793
N/A
48 627
-13%
57 798
+19%
Shares Outstanding
Common Shares Outstanding
16
16
16

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 317,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.